Back

Multi-dimensional optimization of a lysin towards a ribolysin against life-threatening S. aureus infections: Fc-LysM-CHAP and its strong synergy with standard of care antibiotics

Badarau, A.; Bauer, B.; Visram, Z.; Qiao, R.; Majoros-Hashempour, A.; Söllner, J.; Durica-Mitic, S.; Dunne, O. M.; Kluj, R.; Kestemont, D.; Kieninger, A.-K.; Kulig, M.; Berdaguer, R.; Schwebs, T.; Zerbs, M.; Czermak, P.; von Freyberg, M.; Schmidt, J.; Schmidberger, L.; Mayer, D.; Protano, M.; Miller, H. A.; Palowitch, G. M.; Dulberger, C. L.; Massaro, M.; Ivanisenko, N.; Jacomet, H.; Ngatcha Bakoue, D.; Oteri, F.; Sela, G.; Corsini, L.

2026-04-28 microbiology
10.64898/2026.04.27.720530 bioRxiv
Show abstract

Bacterial lysins are promising novel antimicrobials but are limited by poor pharmacokinetics and challenging manufacturability. We developed a lysin discovery platform tailored for lysin delivery via mRNA: staphylococcal LysM-CHAP (cysteine, histidine-dependent amidohydrolases/peptidase) autolysin was selected and its serum half-life extended via Immunoglobulin G1-Fc-fusion. The Fc-induced drop in lysin potency was rescued by the concerted optimization of linkers, binding kinetics and catalytic activity, using a combination of rational and AI-guided approaches. The engineered Fc-LysM-CHAP was active against planktonic bacteria (minimum inhibitory concentration of 1 - 2 {micro}g/mL) and simulated endocardial vegetations and synergized strongly (Fractional eradication concentration index FECI = 0.06) with cell wall active antibiotics in vitro. In mouse models of Staphylococcus aureus sepsis, the recombinant Fc-LysM-CHAP - antibiotic combination was superior to single agent treatments and mRNA-delivered Fc-LysM-CHAP showed single agent activity at a mRNA-lipid nanoparticle dose as low as 0.2 mg/kg.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

1
Nature Communications
○ 5641 papers in training set
Top 0.6%
40.1%
Similar papers in this journal
2
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 7%
6.3%
Similar papers in this journal
3
Nature
○ 645 papers in training set
Top 3%
5.6%
Similar papers in this journal
50% of probability mass above
4
Nature Microbiology
○ 155 papers in training set
Top 0.8%
4.1%
Similar papers in this journal
5
Science Advances
● 1243 papers in training set
Top 11%
3.2%
Similar papers in this journal
6
eLife
● 5828 papers in training set
Top 38%
2.8%
7
Cell Reports
○ 1498 papers in training set
Top 14%
2.7%
8
Cell Reports Medicine
○ 153 papers in training set
Top 1%
2.4%
9
Nature Chemical Biology
○ 119 papers in training set
Top 1%
2.4%
10
Immunity
○ 67 papers in training set
Top 0.8%
2.1%
11
Nature Medicine
○ 125 papers in training set
Top 1%
2.1%
12
Cell Host & Microbe
126 papers in training set
Top 1%
1.8%
13
Cell Research
○ 51 papers in training set
Top 0.5%
1.8%
14
ACS Central Science
● 71 papers in training set
Top 0.8%
1.5%
15
Cell Chemical Biology
○ 94 papers in training set
Top 0.8%
1.5%
16
Signal Transduction and Targeted Therapy
○ 30 papers in training set
Top 0.3%
1.5%
17
Cell
○ 431 papers in training set
Top 8%
1.1%
18
Communications Biology
○ 993 papers in training set
Top 20%
1.1%
19
Science
● 477 papers in training set
Top 8%
1.1%
20
mBio
● 833 papers in training set
Top 11%
0.9%
21
The EMBO Journal
○ 309 papers in training set
Top 6%
0.9%
22
Nature Biotechnology
○ 172 papers in training set
Top 4%
0.9%
23
eBioMedicine
○ 183 papers in training set
Top 6%
0.9%
24
Journal of Experimental Medicine
● 119 papers in training set
Top 3%
0.6%
25
Science Translational Medicine
● 127 papers in training set
Top 4%
0.6%
26
Journal of Clinical Investigation
● 179 papers in training set
Top 6%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.